NervGen Pharma Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
5.5%projected annual EPS growth
Analyst Coverage
7analysts covering
FY EPS (est.)
-$0.19next fiscal year
Monitoring Framework
Key Performance Indicators
RESTORE Phase 3 Registrational Study Initiation QuarterlyTarget: Initiation of patient dosing and site activation in mid-2026
Cash and Investments Balance Quarterly16.6MTarget: Sufficient capital to fund operations and clinical development plans, bolstered by a US$60.0 million public offering in May 2026
GRASSP Quantitative Prehension (QtP) Mean Improvement Annually3.7Target: Exceed the 2.0-point minimally important difference in the Phase 3 RESTORE trial (CONNECT SCI Phase 1b/2a achieved +3.7 points vs +0.4 points for placebo)
Watch Items
- RESTORE Phase 3 Trial Site Activation and Patient EnrollmentTrigger: Delays in activating clinical sites beyond mid-2026Action: Re-evaluate clinical operations strategy, patient recruitment outreach, and clinical trial site support
- Cash Burn Rate and Capital RunwayTrigger: Quarterly cash burn exceeding projected R&D and G&A budgets without corresponding clinical milestonesAction: Utilize the US$50.0 million ATM equity program established with Leerink Partners or optimize operational expenditures
- Regulatory Alignment and Indication Prioritization FrameworkTrigger: Failure to communicate the prioritized clinical indication framework for NVG-291 expansion in mid-2026Action: Accelerate translational research reviews and align with regulatory advisors on secondary indications
Research as of 24 Jul 2026